Empower Your Fight Against Neuroendocrine Tumors
Neuroendocrine tumors are a complex, systemic illness. Investigate their mechanism and discover how protecting your living functional tumor tissue establishes a cornerstone for personalized medicine mapping.
Talk to a Care SpecialistWhat are Neuroendocrine Tumors?
Neuroendocrine tumors (NETs) are a rare form of cancer that emerges from specialized cells of the body's neuroendocrine system. These specialized cells exist throughout the body, meaning NETs can develop nearly anywhere, but most commonly strike the gastrointestinal tract, the pancreas, and the lungs.
Unlike standard solid tumors, NETs retain the ability of the cells they originated from—specifically, the capacity to produce and secrete hormones powerfully directly into the bloodstream.
What Do NETs Do?
The severity lies not only in the physical growth of the tumor but in its massive regulation-disrupting hormone secretion.
- Carcinoid Syndrome: When NETs secrete excess serotonin and other chemicals, they cause debilitating flushing, severe diarrhea, and asthma-like wheezing.
- Systemic Overload: Overactive hormone release violently disrupts normal blood sugar and vascular regulation, putting immense strain on the heart and other critical systems.
- Indolent yet Aggressive: While many NETs grow incredibly slowly, deceiving patients, they can stealthily metastasize significantly before being discovered.
Current Treatment Options
Somatostatin Analogs
Advanced drug therapies designed not strictly to kill the tumor, but to halt the out-of-control hormone secretion that causes Carcinoid Syndrome.
PRRT (Peptide Receptor Radionuclide Therapy)
A sophisticated molecular therapy delivering high doses of radiation intravenously straight into the NET cells utilizing specific protein markers.
Surgical Debulking
Because these tumors synthesize dangerous hormones, surgically removing as much of the mass as possible drastically diminishes systemic symptoms.
Why Bank Your Living NETs Tissue?
NETs are deeply individual—no two secrete exact hormonal panels or mutate identically. When surgery clears them, hospitals frequently destroy the only living evidence of the cancer's operational structure. KernisHealth keeps it alive for functional verification.
Targeted Receptor Testing
Living models grant oncologists the ability to directly test if novel systemic therapies appropriately latch to your unique cell receptors before administration.
Hormonal Interaction Mapping
3D culturing of NET cells permits an off-body evaluation of which combination of blocking agents effectively curbs toxic hormone secretions.
Clinical Trial Readiness
Maintaining pristine cellular integrity opens rapid-entry pathways to evolving radionuclide trials requiring fresh receptor profiling.
Future-Proofing Your Care
Since NETs commonly recur very slowly over years, a biobanked sample ensures mapping from your original biology remains securely accessible for comparison over time as medicine upgrades.